|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ɫ���� |
|
ϸ�������� |
|
���� |
| ��������������� | |
|
���Ѿ� |
|
������ |
| PubMed | |
|
Article by FU You-jun |
|
Article by MA Peng-cheng |
ϸ���������ƺ������Ľ�չ
���Ѿ�, ������
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
���������ѳ�Ϊ���Ժ��������Ʒ�֮һ,��������¡���塢ϸ�����ӡ���������ȶ��ַ���������ϸ���������ƺ����������ý������������ǹ�ע������ϸ����������ء������ء������������ӡ�����̼��������ƺ��������о���չ��һ����,��ʾϸ�����Ӽ��������Ʒ������ƺ����������е���Ҫ��λ��
Cytokine Therapy for Melanoma
Institute of Dermatology, Chinese Acad-emy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Acad-emy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Immunotherapy for malignant melanoma includes monoclonal antibody, cytokine, and vaccination approaches. Of them, cytokine therapy is the focus of recent researches. This article reviews the progress in melanoma immunotherapy with an emphasis on various cytokines, including interleukins, interferons, tumor necrosis factors and colony stimulating factors. The monotherapy and combination therapy with cytokines play important roles in the treatment of melanoma.
[2] anelli MC,Wang E,Phan G,et al.Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.Genome Biol,2002,3:research0035.
[3] Mortarini R,Borri A,Tragni G,et al.Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.Cancer Res,2000,60:3559-3568.
[4] Gollob JA,Mier JW,Veenstra K,et al.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma:ability to maintain IFN-gamma induction is associated with clinical response.Clin Cancer Res,2000,6:1678-1692.
[5] Gollob JA,Veenstra KG,Parker RA,et al.Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.J Clin Oncol,2003,21:2564-2573.
[6] Lesinski GB,Badgwell B,Zimmerer J,et al.IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.J Immunol,2004,172:7368-7376.
[7] Alatrash G,Hutson TE,Molto L,et al.Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b:phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.J Clin Oncol,2004,22:2891-2900.
[8] Klebanoff CA,Finkelstein SE,Surman DR,et al.IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.Proc Natl Acad Sci U S A,2004,101:1969-1974.
[9] Parrish-Novak J,Dillon SR,Nelson A,et al.Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.Nature,2000,408:57-63.
[10] Ma HL,Whitters MJ,Konz RF,et al.IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.J Immunol,2003,171:608-615.
[11] Wang G,Tschoi M,Spolski R,et al.In vivo antitumor activity of interleukin 21 mediated by natural killer cells.Cancer Res,2003,63:9016-9022.
[12] Kirkwood JM,Richards T,Zarour HM,et al.Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma:the E2690 laboratory corollary of intergroup adjuvant trial E1690.Cancer,2002,95:1101-1112.
[13] Muggiano A,Mulas C,Fiori B,et al.Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.Melanoma Res,2004,14:S1-7.
[14] Eggermont AM,Suciu S,MacKie R,et al.Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage ��b/�� melanoma (EORTC 18952):randomised controlled trial.Lancet,2005,366:1189-1196.
[15] Guillot B,Portales P,Thanh AD,et al.The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.Br J Dermatol,2005,152:690-696.
[16] Menon C,Iyer M,Prabakaran I,et al.TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model.Am J Physiol Heart Circ Physiol,2003,284:H317.
[17] Poehlein CH,Hu HM,Yamada J,et al.TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.J Immunol,2003,170:2004-2013.
[18] O'Day SJ,Boasberg PD,Piro L,et al.Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.Clin Cancer Res,2002,8:2775-2781.